BioMarin Pharmaceuticals (BMRN) Misses Q4 EPS by 12c; Guides FY12 Revs Below
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $55.47 +1.43%
Revenue Growth %: +13.2%
Financial Fact:
Research and development: 160.83M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +13.2%
Financial Fact:
Research and development: 160.83M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported Q4 EPS of ($0.23), $0.12 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $107.9 million versus the consensus estimate of $115.3 million.
Sees FY2012 revenue of $465-$510 million, versus the consensus of $512.6 million.
For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.
Sees FY2012 revenue of $465-$510 million, versus the consensus of $512.6 million.
For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AeroVironment restates quarterly financials, citing $89M goodwill error
- Morgan Stanley Resumes Global Payments (GPN) at Equalweight
- CRH agrees to buy Arcosa in $8.5B all-cash deal
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
